<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>Latest Medical Technology from Bio-Medicine.Org</title>
<link>http://www.bio-medicine.org/medicine-technology-1/</link>
<description>Latest Medical Technology lists</description>
<language>en-us</language>
<copyright>Copyright 2007. Bio-Medicine All Rights Reserved.</copyright>
<item>
<title><![CDATA[Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Hereditary-Angioedema-Patients-Report-3A-C1-Esterase-Inhibitor-Concentrate-Effective-in-Treating-Acute-Attacks--Helps-Them-Avoid-Emergency-Care-6070-1/</link>
<pubDate>Sat, 07 Nov 2009 07:07:23 MST</pubDate>
<description><![CDATA[MIAMI BEACH, Fla., Nov. 7 /- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Meeting. The results come from a self-reported su... ]]></description>
</item>
<item>
<title><![CDATA[Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Prodromal-Symptoms-Warn-of-Hereditary-Angioedema-Attacks--Give-Patients-Time-to-Start-Therapy-and-Decrease-Morbidity-6069-1/</link>
<pubDate>Sat, 07 Nov 2009 07:07:15 MST</pubDate>
<description><![CDATA[MIAMI BEACH, Fla., Nov. 7 /- Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Meeti... ]]></description>
</item>
<item>
<title><![CDATA[SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/SCOLR-Pharma--Inc--Reports-Third-Quarter-2009-Financial-Results-6068-1/</link>
<pubDate>Fri, 06 Nov 2009 07:50:48 MST</pubDate>
<description><![CDATA[BOTHELL, Wash., Nov. 6 /- SCOLR Pharma, Inc. (Amex:  DDD ) today reported financial results for the three and nine months ended September 30, 2009.         Stephen J. Turner, SCOLR Pharma's President and CEO, said, "We continue to advance discussions related to licensing our 12-hour ibuprofen formulation. Several potential partners have committed significant resource... ]]></description>
</item>
<item>
<title><![CDATA[Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Oxygen-Biotherapeutics--Inc--Announces-1-3A15-Reverse-Stock-Split-to-Take-Effect-Nov--9--2009-6067-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:52 MST</pubDate>
<description><![CDATA[DURHAM, N.C., Nov. 6 /- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that a previously approved reverse split of its common stock will take effect at the start of trading on Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted basis. Oxygen Biotherapeutics, Inc. shares will trade under the new symbol OXBT. The stock also will have a new CUSIP... ]]></description>
</item>
<item>
<title><![CDATA[Recession Continues to Depress Sales at Allied Healthcare Products]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Recession-Continues-to-Depress-Sales-at-Allied-Healthcare-Products-6066-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:47 MST</pubDate>
<description><![CDATA[ST. LOUIS, Nov. 6 /- Recession in domestic and international markets continued to depress sales for Allied Healthcare Products in the first quarter of fiscal year 2010 ending September 30, 2009.       Sales declines pushed Allied into a loss for the quarter.  The net loss for the quarter was about $745,000, or negative 9 cents per share, compared to a net profit the... ]]></description>
</item>
<item>
<title><![CDATA[McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/McNeil-Consumer-Healthcare-Announces-Voluntary-Recall-of-Certain-Lots-of-TYLENOL-28R-29-Arthritis-Pain-100-Count-with-EZ-OPEN-CAP-6065-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:39 MST</pubDate>
<description><![CDATA[FORT WASHINGTON, Pa., Nov. 6 /- In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is initiating a voluntary recall of a limited number of product lots of TYLENOL&#174; Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP. McNeil is initiating the recall after identifyin... ]]></description>
</item>
<item>
<title><![CDATA[DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/DUSA-Pharmaceuticals-to-Present-at-the-Merriman-Curhan-Ford-Investor-Summit-2009-6064-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:36 MST</pubDate>
<description><![CDATA[WILMINGTON, Mass., Nov. 6 /- DUSA Pharmaceuticals, Inc.(&#174;) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(&#174;) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curha... ]]></description>
</item>
<item>
<title><![CDATA[Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Trius-Therapeutics-Files-Registration-Statement-for-Proposed-Initial-Public-Offering-6063-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:33 MST</pubDate>
<description><![CDATA[SAN DIEGO, Nov. 6 /- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.       Credit Suisse Securities (USA) LL... ]]></description>
</item>
<item>
<title><![CDATA[Watson to Present at Credit Suisse Healthcare Conference]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Watson-to-Present-at-Credit-Suisse-Healthcare-Conference-6062-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:30 MST</pubDate>
<description><![CDATA[MORRISTOWN, N.J., Nov. 6 /- Watson Pharmaceuticals, Inc. (NYSE:  WPI ), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, 2009 at 12:00 pm Eastern St... ]]></description>
</item>
<item>
<title><![CDATA[Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Kaiser-Foundation-Health-Plan-and-Hospitals-Report-Third-Quarter-2009-Financial-Results-6061-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:27 MST</pubDate>
<description><![CDATA[OAKLAND, Calif., Nov. 6 /- Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals (KFHP/H), and their subsidiaries reported today a combined total operating revenue of $10.5 billion for the quarter ended September 30, 2009, compared to $10.2 billion in the third quarter of last year. Operating income in the third quarter was $336 million, compared to $307 million in... ]]></description>
</item>
<item>
<title><![CDATA[NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/NasTrac-Quarterly-Index-Shows-Decline-in-Trucking-and-Machine-Tool-Repossessions-in-Q3-2009-6060-1/</link>
<pubDate>Fri, 06 Nov 2009 01:28:15 MST</pubDate>
<description><![CDATA[WESTBURY, N.Y., Nov. 6 /- Repossessions and liquidations of trucking equipment and machine tools in the third quarter of 2009 declined as compared to similar figures from 2008, according to Nassau Asset Management's NasTrac Quarterly Index (NQI).  The figures, culled from the company's activity reports for both repossessions and orderly liquidations, also indicated a rise in r... ]]></description>
</item>
<item>
<title><![CDATA[Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll &amp; Traffic Businesses]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Roper-Industries-Announces-Two-Acquisitions-to-Enhance-Growth-in-Medical-and-Toll--26amp-3B-Traffic-Businesses-6059-1/</link>
<pubDate>Fri, 06 Nov 2009 01:28:05 MST</pubDate>
<description><![CDATA[SARASOTA, Fla., Nov. 6 /-  Roper Industries, Inc.  (NYSE: ROP)   today announced that it has signed a definitive agreement to acquire Verathon, Inc., a leading provider of proprietary medical devices.  The Verathon Board of Directors has approved the transaction and the closing is subject to customary regulatory approvals and closing conditions, including shareholder... ]]></description>
</item>
<item>
<title><![CDATA[Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Caraco-Pharmaceutical-Laboratories--Ltd--Markets-Generic-Acular-28R-29-Ophthalmic-Solution-6058-1/</link>
<pubDate>Fri, 06 Nov 2009 01:27:52 MST</pubDate>
<description><![CDATA[DETROIT, Nov. 6 /- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex:  CPD ) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular&#174; ophthalmic solution on the first day following patent expiration. This s... ]]></description>
</item>
<item>
<title><![CDATA[Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Partnership-for-Prescription-Assistance-Prepared-to-Help-Southern-Workers-Hurt-by-Recession-6057-1/</link>
<pubDate>Fri, 06 Nov 2009 01:27:48 MST</pubDate>
<description><![CDATA[CHARLESTON, S.C.,   Nov. 6 /PRNewswire-USNewswire/ -- The 'Help is Here Express' bus tour will be stopping in South Carolina and Georgia throughout the week of November 9-13 at various cities in order to help uninsured and financially-struggling patients access information on programs that provide prescription medicines for free or nearly free. With the nation's unemployment rate now hitti... ]]></description>
</item>
<item>
<title><![CDATA[Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962)]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Statement-of-Americas-Specialty-Medicines-Companies-On-House-Health-Care-Bill--28H-R--3962-29-6056-1/</link>
<pubDate>Fri, 06 Nov 2009 01:27:41 MST</pubDate>
<description><![CDATA[WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- America's Specialty Medicines Companies (ASMC), an informal working group of mid-market and smaller innovator pharmaceutical companies, today expressed concerns about H.R. 3962, the "Affordable Health Care for America Act," introduced by House Democrats last Thursday.  These smaller companies fear that the cumulative effect of a host of provisi... ]]></description>
</item>
<item>
<title><![CDATA[Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Derma-Sciences-Announces-Date-of-Its-Third-Quarter-2009-Earnings-Release-and-Conference-Call-6055-1/</link>
<pubDate>Fri, 06 Nov 2009 08:17:59 MST</pubDate>
<description><![CDATA[PRINCETON, N.J., Nov. 6 /-   Derma Sciences, Inc.   (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced plans to release its third quarter 2009 results before market on Monday, November 16, 2009. The Company will hold a conference call that same day to discuss the results at 11:00 am EST. Interested parties should call (866) 788-0546 (do... ]]></description>
</item>
<item>
<title><![CDATA[Facet Solutions Acquires Archus Orthopedics]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Facet-Solutions-Acquires-Archus-Orthopedics-6054-1/</link>
<pubDate>Fri, 06 Nov 2009 08:17:54 MST</pubDate>
<description><![CDATA[HOPKINTON, Mass., Nov. 6 /- Facet Solutions, Inc. announced today that it has acquired all of the assets of Archus Orthopedics. The acquisition creates an undisputed leadership position in product offerings, intellectual property and clinical experience in posterior motion preservation. "This is a win for patients suffering from lumbar spinal stenosis," stated Facet Solutions'... ]]></description>
</item>
<item>
<title><![CDATA[NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/NuVasive-Appoints-New-Chief-Financial-Officer-and-Announces-Additional-Management-Updates-6053-1/</link>
<pubDate>Fri, 06 Nov 2009 08:17:49 MST</pubDate>
<description><![CDATA[SAN DIEGO, Nov. 6 /- NuVasive, Inc. (Nasdaq:  NUVA ), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today the appointment of Michael J. Lambert as Executive Vice President and Chief Financial Officer, effective November 9, 2009.  The Company also announced several other Executive Manageme... ]]></description>
</item>
<item>
<title><![CDATA[Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Boston-Scientific-Announces-Agreement-With-DOJ-On-Pre-Acquisition-Investigation-of-Guidant-6052-1/</link>
<pubDate>Fri, 06 Nov 2009 08:17:42 MST</pubDate>
<description><![CDATA[NATICK, Mass., Nov. 6 /- Boston Scientific Corporation (NYSE:  BSX ) today announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005.  The alleged conduct and product sales occurred prior to Boston Scientific's 2006 acquisition of Guidant.       Boston Scien... ]]></description>
</item>
<item>
<title><![CDATA[OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/OTCBB-VHGI-Updates-Shareholders-on-Status-of-Healthcare-Asset-Sale-and-Treasure-Gulch-Gold-Mine-Development-Strategy-6051-1/</link>
<pubDate>Fri, 06 Nov 2009 08:17:25 MST</pubDate>
<description><![CDATA[LEXINGTON, Ky., Nov. 6 /- Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI) confirmed today that the previously confirmed Letter of Intent to sell all health care related assets to Wound Management Technologies, Inc (WNDM) is subject to final approval  of the Board of Directors and shareholders of VHGI.          Shareholder Assurances        "We believe th... ]]></description>
</item>
</channel>
</rss>